{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:32:48Z","timestamp":1793212368313,"version":"4.5.0"},"reference-count":37,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Acquired hemophilia A (AHA) is a severe bleeding disorder caused by inhibiting autoantibodies to coagulation factor VIII (FVIII). For hemostatic treatment, bypassing agents and human or porcine FVIII are currently standard of care. Emicizumab is a bispecific, FVIII-mimetic therapeutic antibody that reduced the annualized bleeding rates in congenital hemophiliacs. Here, we report on 6 male and 6 female patients with AHA treated with emicizumab (all data medians and interquartile range), age 74 (64-80) years,\u00a0initial FVIII &amp;lt;1%; inhibitor titer 22.3 Bethesda units (BU)\/mL (range, 3-2000). Eight patients had severe bleeding. Emicizumab was started, 3 mg\/kg subcutaneously, weekly for 2 to 3 doses, followed by 1.5 mg\/kg every 3 weeks to keep the lowest effective FVIII levels. For FVIII monitoring, chromogenic assays with human and bovine reagents were used. All patients received immunosuppression with steroids and\/or rituximab. After the first dose of emicizumab, activated partial thromboplastin time normalized in 1 to 3 days, FVIII (human reagents) exceeded 10% after 11 (7.5-12) days. Hemostatic efficacy was obtained and bypassing therapy stopped after 1.5 (1-4) days. FVIII (bovine reagents) exceeded 50%, indicating complete remission after 115 (67-185) days, and emicizumab was stopped after 31 (15-79) days. A median of 5 injections (range, 3-9) were given. No patient died of bleeding or thromboembolism, and no breakthrough bleeding was observed after the first dose of emicizumab. In conclusion, emicizumab seems to be an effective hemostatic therapy for AHA, with the advantages of subcutaneous therapy, good hemostatic efficacy, early discharge, and reduction of immunosuppression and adverse events.<\/jats:p>","DOI":"10.1182\/blood.2020006315","type":"journal-article","created":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T22:55:11Z","timestamp":1596840911000},"page":"410-419","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":142,"title":["Emicizumab for the treatment of acquired hemophilia A"],"prefix":"10.1182","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7909-7225","authenticated-orcid":false,"given":"Paul","family":"Knoebl","sequence":"first","affiliation":[{"name":"Division for Hematology and Hemostasis, Department of Medicine 1, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9613-8658","authenticated-orcid":false,"given":"Johannes","family":"Thaler","sequence":"additional","affiliation":[{"name":"Division for Hematology and Hemostasis, Department of Medicine 1, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9620-0813","authenticated-orcid":false,"given":"Petra","family":"Jilma","sequence":"additional","affiliation":[{"name":"Coagulation Laboratory, Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0122-8213","authenticated-orcid":false,"given":"Peter","family":"Quehenberger","sequence":"additional","affiliation":[{"name":"Coagulation Laboratory, Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5753-0203","authenticated-orcid":false,"given":"Karoline","family":"Gleixner","sequence":"additional","affiliation":[{"name":"Division for Hematology and Hemostasis, Department of Medicine 1, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang R.","family":"Sperr","sequence":"additional","affiliation":[{"name":"Division for Hematology and Hemostasis, Department of Medicine 1, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"18","key":"2021012116214043300_B1","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s40265-018-1027-y","article-title":"Prevention and management of bleeding episodes in patients with acquired hemophilia A","volume":"78","author":"Kn\u00f6bl","year":"2018","journal-title":"Drugs"},{"issue":"3","key":"2021012116214043300_B2","first-page":"498","article-title":"Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management","volume":"13","author":"Franchini","year":"2015","journal-title":"Blood Transfus"},{"issue":"4","key":"2021012116214043300_B3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.5482\/HAMO-14-11-0064","article-title":"Management of acquired haemophilia A","volume":"35","author":"Tiede","year":"2015","journal-title":"Hamostaseologie"},{"issue":"9","key":"2021012116214043300_B4","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1080\/10245332.2017.1319115","article-title":"Acquired hemophilia A: a review of recent data and new therapeutic options","volume":"22","author":"Franchini","year":"2017","journal-title":"Hematology"},{"issue":"7","key":"2021012116214043300_B5","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3324\/haematol.2019.230771","article-title":"International recommendations on the diagnosis and treatment of acquired hemophilia A","volume":"105","author":"Tiede","year":"2020","journal-title":"Haematologica"},{"issue":"4","key":"2021012116214043300_B6","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1538-7836.2012.04654.x","article-title":"Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)","volume":"10","author":"Knoebl","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2021012116214043300_B7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2012-02-408930","article-title":"Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry","volume":"120","author":"Baudo","year":"2012","journal-title":"Blood"},{"issue":"7","key":"2021012116214043300_B8","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/ajh.24777","article-title":"Acquired hemophilia A: updated review of evidence and treatment guidance","volume":"92","author":"Kruse-Jarres","year":"2017","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"2021012116214043300_B9","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S0268-960X(15)30004-7","article-title":"The use of recombinant activated factor VII in patients with acquired haemophilia","volume":"29","author":"Tiede","year":"2015","journal-title":"Blood Rev"},{"issue":"10","key":"2021012116214043300_B10","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s00277-018-3372-z","article-title":"Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia [published correction appears in Ann Hematol. 2018;97(12):2531]","volume":"97","author":"Tiede","year":"2018","journal-title":"Ann Hematol"},{"issue":"2","key":"2021012116214043300_B11","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/hae.12627","article-title":"Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A","volume":"21","author":"Kruse-Jarres","year":"2015","journal-title":"Haemophilia"},{"issue":"1","key":"2021012116214043300_B12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/jth.14618","article-title":"Cross-reacting inhibitors against recombinant porcine factor VIII in acquired hemophilia A: data from the GTH-AH 01\/2010 study","volume":"18","author":"T\u00fcrkantoz","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2021012116214043300_B13","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/bjh.16128","article-title":"Outcome of CARE: a 6-year national registry of acquired haemophilia A in China","volume":"187","author":"Sun","year":"2019","journal-title":"Br J Haematol"},{"key":"2021012116214043300_B14","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.thromres.2018.12.006","article-title":"Low dose of aPCC after the initial treatment in acquired haemophilia A is useful to reduce bleeding relapses: Data from the FAIR registry","volume":"174","author":"Zanon","year":"2019","journal-title":"Thromb Res"},{"issue":"1","key":"2021012116214043300_B15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2012-02-409185","article-title":"Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)","volume":"120","author":"Collins","year":"2012","journal-title":"Blood"},{"issue":"7","key":"2021012116214043300_B16","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood-2014-07-587089","article-title":"Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01\/2010 study","volume":"125","author":"Tiede","year":"2015","journal-title":"Blood"},{"issue":"19","key":"2021012116214043300_B17","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1182\/blood-2015-09-672774","article-title":"Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01\/2010 study","volume":"127","author":"Tiede","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2021012116214043300_B18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00277-008-0665-7","article-title":"Immunosuppressive treatment for acquired haemophilia: current practice and future directions in Germany, Austria and Switzerland","volume":"88","author":"Tiede","year":"2009","journal-title":"Ann Hematol"},{"issue":"9","key":"2021012116214043300_B19","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1182\/blood-2002-03-0765","article-title":"Rituximab in the treatment of acquired factor VIII inhibitors","volume":"100","author":"Wiestner","year":"2002","journal-title":"Blood"},{"issue":"1","key":"2021012116214043300_B20","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3324\/haematol.10553","article-title":"Rituximab for the treatment of acquired antibodies to factor VIII","volume":"92","author":"Sperr","year":"2007","journal-title":"Haematologica"},{"issue":"5","key":"2021012116214043300_B21","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/bjh.12829","article-title":"Inhibitor eradication with rituximab in haemophilia: where do we stand?","volume":"165","author":"Franchini","year":"2014","journal-title":"Br J Haematol"},{"issue":"5","key":"2021012116214043300_B22","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/jth.13304","article-title":"Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH-AH 01\/2010 study","volume":"14","author":"Werwitzke","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"9","key":"2021012116214043300_B23","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia a without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"2021012116214043300_B24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/hae.13618","article-title":"The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 study","volume":"25","author":"Oldenburg","year":"2019","journal-title":"Haemophilia"},{"issue":"12","key":"2021012116214043300_B25","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1080\/03007995.2019.1649378","article-title":"Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial","volume":"35","author":"Reyes","year":"2019","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"2021012116214043300_B26","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol"},{"issue":"9","key":"2021012116214043300_B27","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"2021012116214043300_B28","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000497287","article-title":"Emicizumab in the treatment of acquired haemophilia: a case report","volume":"46","author":"M\u00f6hnle","year":"2019","journal-title":"Transfus Med Hemother"},{"issue":"3","key":"2021012116214043300_B29","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/rth2.12201","article-title":"Successful use of emicizumab in a patient with refractory acquired hemophilia A and acute coronary syndrome requiring percutaneous coronary intervention","volume":"3","author":"Dane","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"2021012116214043300_B30","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.12659\/AJCR.916783","article-title":"Emicizumab use in treatment of acquired hemophilia A: a case report","volume":"20","author":"Al-Banaa","year":"2019","journal-title":"Am J Case Rep"},{"issue":"7","key":"2021012116214043300_B31","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1055\/s-0039-1688687","article-title":"Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays","volume":"119","author":"Adamkewicz","year":"2019","journal-title":"Thromb Haemost"},{"issue":"6","key":"2021012116214043300_B32","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/jth.14784","article-title":"Laboratory testing in hemophilia: impact of factor and non-factor replacement therapy on coagulation assays","volume":"18","author":"Peyvandi","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"21","key":"2021012116214043300_B33","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A","volume":"374","author":"Shima","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"2021012116214043300_B34","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/hae.13844","article-title":"Clinical evaluation of bleeds and response to haemostatic treatment in patients with acquired haemophilia: a global expert consensus statement","volume":"25","author":"Tiede","year":"2019","journal-title":"Haemophilia"},{"issue":"6","key":"2021012116214043300_B35","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/cpdd.617","article-title":"Relative and absolute bioavailability study of emicizumab to bridge drug products and subcutaneous injection sites in healthy volunteers","volume":"8","author":"Kotani","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"3","key":"2021012116214043300_B36","first-page":"279","article-title":"Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01\/2010 study","volume":"136","author":"Holstein","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2021012116214043300_B37","first-page":"128","article-title":"Surgical experience in two multicentre, open-label phase 3 studies of emicizumab in persons with haemophilia a with inhibitors (haven 1 and haven 2) [abstract]","volume":"181","author":"Kruse-Jarres","year":"2018","journal-title":"Br J Haematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/3\/410\/1797631\/bloodbld2020006315.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/3\/410\/1797631\/bloodbld2020006315.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T16:40:21Z","timestamp":1611247221000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/137\/3\/410\/461764\/Emicizumab-for-the-treatment-of-acquired"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,21]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,1,21]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020006315","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,21]]}}}